Defence Therapeutics Announces Convertible Debenture Interest Payment
Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company. The Company announces that, in accordance with the terms and conditions of convertible debentures...